The fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called on the government to implement a little-known law allowing to set aside patents and provide drugs for the benefit of society at a much cheaper price.
A patient-led pressure group, Just Treatment, has joined with campaigners who want Vertex’s cystic fibrosis drug Orkambi to be funded by the NHS, and last night lobbied the government to implement the so-called “Crown use” law.
Under provisions in the 1977 Patents Act, the government could allow another manufacturer to make Orkambi and pay Vertex a royalty that would be much lower than the list price of around £104,000 per patient per year.